Jungian cognitive functions

Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia

Retrieved on: 
Monday, December 11, 2023

TRANSCEND FL is the largest clinical trial to date to evaluate a CAR T cell therapy in patients with relapsed or refractory indolent non-Hodgkin lymphoma, including FL.

Key Points: 
  • TRANSCEND FL is the largest clinical trial to date to evaluate a CAR T cell therapy in patients with relapsed or refractory indolent non-Hodgkin lymphoma, including FL.
  • Additionally, the company presented long-term data from the TRANSCEND CLL 004 study evaluating Breyanzi in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) with 24-month follow-up ( Oral Presentation #330 ).
  • Bristol Myers Squibb (BMS) has the broadest ongoing cell therapy development program in CD19-positive malignancies with Breyanzi, which also includes trials investigating its use in patients with relapsed/refractory mantle cell lymphoma (MCL).
  • In the TRANSCEND FL clinical trial, 130 patients with relapsed or refractory follicular lymphoma (FL) were enrolled and treated with Breyanzi in the second-line and third-line plus settings.

New Promising Research Results: The Brain Balance Program Improves Attention and Classroom Behavior in Students with Attentional and Developmental Challenges in a School Setting

Retrieved on: 
Thursday, September 14, 2023

New Study: the Brain Balance program improves attention and behavior in students in a school setting.

Key Points: 
  • New Study: the Brain Balance program improves attention and behavior in students in a school setting.
  • "We are excited to present these promising findings from the School Pilot Study," said Dominick Fedele, Chief Executive Officer at Brain Balance Centers.
  • "The results demonstrate the potential impact of the Brain Balance program in improving classroom behavior and attention in students with attentional and developmental challenges."
  • The Brain Balance program takes a unique whole-child approach, integrating multiple domains of development to address the underlying challenges faced by children with attentional and developmental issues.

NisonCo, America’s First Cannabis-Centric PR Firm, Celebrates a Decade of Advocacy and Adaptability

Retrieved on: 
Tuesday, July 18, 2023

NisonCo’s first public relations clients came from word of mouth, and over the years, NisonCo has expanded its service offerings and client list.

Key Points: 
  • NisonCo’s first public relations clients came from word of mouth, and over the years, NisonCo has expanded its service offerings and client list.
  • Their nearly 150 client record run the gamut from large multi-state operators (MSOs) to start-ups, nonprofits, and individual entrepreneurs.
  • Many team members pursue activism in their free time, and NisonCo works to support a culture of advocacy at work and beyond.
  • “It’s been incredible to see this organization grow over the past decade,” says NisonCo Founder and President Evan Nison.

Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer’s Disease (AD)

Retrieved on: 
Wednesday, June 7, 2023

The open-label study enrolled 8 patients with confirmed presence of brain amyloid pathology and baseline MMSE scores between 12 and 25.

Key Points: 
  • The open-label study enrolled 8 patients with confirmed presence of brain amyloid pathology and baseline MMSE scores between 12 and 25.
  • The patients were treated with five day-courses of COYA 301 for four monthly cycles and were followed for two months post-treatment.
  • In addition to COYA 301 administration resulting in a statistically significant reduction of blood biomarkers CCL11, CCL2, and IL-15.
  • The PET scan after the last cycle of COYA 301 showed marked reduction in TSPO binding across the brain representing lowered inflammation.

Greg Lindberg Explains in His Latest Book Hormesis and Its Connection to Wellness and Longevity

Retrieved on: 
Wednesday, April 12, 2023

ORLANDO, Fla., April 12, 2023 /PRNewswire/ -- Greg Lindberg, entrepreneur, philanthropist and author, explores the concept of hormesis in his latest book 633 Days Inside: Lessons on Life and Leadership. Hormesis is a concept Lindberg details in his book based on his own experiences and self-transformation during a challenging time in his life.

Key Points: 
  • Hormesis is a concept Lindberg details in his book based on his own experiences and self-transformation during a challenging time in his life.
  • Learn more about the book: https://633days.com/book/
    "My mission in life is to help people live happier and healthier," said Lindberg.
  • Lindberg says applying hormesis into day-to-activity can help improve health and wellness, increase focus, slow aging and sharpen the mind.
  • Throughout the book, Lindberg relies on the power of science as a guide for transforming the body and mind using the concept of hormesis.

FTC challenges claims that products could treat side effects of cancer treatment

Retrieved on: 
Saturday, December 17, 2022

But you can add the FTCs settlement with Florida-based CellMark Biopharma and CEO Derek Vest to that list and the deceptive claims they pitched to people battling cancer are particularly disconcerting.

Key Points: 
  • But you can add the FTCs settlement with Florida-based CellMark Biopharma and CEO Derek Vest to that list and the deceptive claims they pitched to people battling cancer are particularly disconcerting.
  • Two serious complications of cancer treatment are cachexia (the wasting syndrome some patients experience) and chemo fog (the chemotherapy-related cognitive dysfunction that patients often report).
  • Selling for $248 for a one-month supply, CellAssure was advertised to treat cachexia and cancer-related malnutrition.
  • In addition, according to the FTC, the defendants conveyed to consumers that CellAssure would improve cancer patients ability to withstand the rigors of surgery, radiation, and chemotherapy.
  • Marketed to treat the memory loss and cognitive impairment sometimes reported during and after chemotherapy, a one-month supply of Cognify cost cancer patients $79.
  • But the case reminds marketers just how seriously the FTC takes claims directed to cancer patients and others battling serious medical conditions.
  • Theres also a message for people dealing with a cancer diagnosis or the side effects of cancer treatment.

Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders

Retrieved on: 
Tuesday, November 22, 2022

Sonlicromanol, Khondrions wholly-owned lead asset, is being investigated in the Phase IIb programme in adult patients with MELAS spectrum disorders as genetically confirmed by the m.3243A>G mutation in the mitochondrial DNA.

Key Points: 
  • Sonlicromanol, Khondrions wholly-owned lead asset, is being investigated in the Phase IIb programme in adult patients with MELAS spectrum disorders as genetically confirmed by the m.3243A>G mutation in the mitochondrial DNA.
  • In line with previous studies, sonlicromanol was found to be safe and well tolerated in the Phase IIb programme, with no serious adverse effects.
  • These longer-term patient data are, therefore, instrumental in providing valuable insights for the design of the upcoming Phase III trial.
  • One of the most advanced disease-modifying drug candidates for mitochondrial disease in development, sonlicromanol has recently completed a Phase IIb study in adult patients with m.3243A>G MELAS spectrum disorders.

Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders

Retrieved on: 
Tuesday, November 22, 2022

Sonlicromanol, Khondrions wholly-owned lead asset, is being investigated in the Phase IIb programme in adult patients with MELAS spectrum disorders as genetically confirmed by the m.3243A>G mutation in the mitochondrial DNA.

Key Points: 
  • Sonlicromanol, Khondrions wholly-owned lead asset, is being investigated in the Phase IIb programme in adult patients with MELAS spectrum disorders as genetically confirmed by the m.3243A>G mutation in the mitochondrial DNA.
  • In line with previous studies, sonlicromanol was found to be safe and well tolerated in the Phase IIb programme, with no serious adverse effects.
  • These longer-term patient data are, therefore, instrumental in providing valuable insights for the design of the upcoming Phase III trial.
  • One of the most advanced disease-modifying drug candidates for mitochondrial disease in development, sonlicromanol has recently completed a Phase IIb study in adult patients with m.3243A>G MELAS spectrum disorders.

GAMMA BrainLuxury™ Named Most Innovative New Supplement Product by News7Health

Retrieved on: 
Monday, November 7, 2022

NEW YORK, Nov. 7, 2022 /PRNewswire/ -- Gerald Thompson, News Editor for News7Health Corp. announced this morning that BrainLuxury, a particularly entrepreneurial and innovative provider of nutritional supplement products for both deeper restorative sleep and enhanced wakeful focus has been named the best in class for its GAMMA BrainLuxury™ formulation. This determination is based upon highly favorable consumer reviews and comparable product research conducted by News7Health.

Key Points: 
  • News7Health has named BrainLuxury's premier GAMMA focus optimization supplement product the most innovative supplement in its class for the fourth quarter of 2022.
  • In an industry overloaded with too many caffeine-infused "focus and alertness" products, GAMMA is truly exceptional in terms of its mechanism of action and its bioavailability.
  • NEW YORK, Nov. 7, 2022 /PRNewswire/ -- Gerald Thompson, News Editor for News7Health Corp. announced this morning that BrainLuxury , a particularly entrepreneurial and innovative provider of nutritional supplement products for both deeper restorative sleep and enhanced wakeful focus has been named the best in class for its GAMMA BrainLuxuryformulation.
  • This determination is based upon highly favorable consumer reviews and comparable product research conducted by News7Health.

At 8.2% CAGR, In-Car Infotainment Market Size is Expected to Reach USD 36.30 Billion in 2028, Says Brandessence Market Research

Retrieved on: 
Friday, January 7, 2022

LONDON, Jan. 7, 2022 /PRNewswire/ -- Global In-Car Infotainment Market size is witness robust growth at a CAGR of 8.2% during the 2021-2028 period.

Key Points: 
  • LONDON, Jan. 7, 2022 /PRNewswire/ -- Global In-Car Infotainment Market size is witness robust growth at a CAGR of 8.2% during the 2021-2028 period.
  • The In-Car Infotainment Market size reached a valuation ofUSD 20.91 Billion in 2021, and is likely to grow to USD 36.30 Billion by 2028 end, Analysis by Brandessence Market Research.
  • The current automotive infotainment market remains a distant dream of its future, wherein advancements like completely automated driving, and growing electric infrastructure remain key trends.
  • According to Brandessence experts, the demands for third-party infotainment remain a key factor for the in-car infotainment market.